GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and other diabetes medications.
在JAMA Network发表的一项研究中，与使用胰岛素和其他糖尿病药物的患者相比，应用GLP-1治疗的2型糖尿病患者患10种与肥胖相关的癌症的风险降低。
GLP-1 treatments, including Novo Nordisk's (NYSE:NVO) semaglutide (Wegvoy and Ozempic) and Eli Lilly And Co's (NYSE:LLY) tirzepatide (Mounjaro and Zepbound), have gained tremendous popularity.
包括诺和诺德（纽约证券交易所：NVO）的塞格列汀（Wegovy and Ozempic）和礼来（纽约证券交易所：LLY）的替西妥肽（Mounjaro and Zepbound）在内的GLP-1疗法已经获得了极大的流行。
The research examined the medical records of 1.6 million diabetes patients with no prior history of thirteen types of obesity-related cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma.
研究调查了160万例没有13种与肥胖相关的癌症病史的糖尿病患者的病历，包括食管癌、结直肠癌、子宫内膜癌、胆囊癌、肾癌、肝癌、卵巢癌、胰腺癌、脑膜瘤和多发性骨髓瘤。
The study did not specify the GLP-1 medications used and analyzed data from patients prescribed GLP-1RAs, insulins, or metformin between March 2005 and November 2018.
研究没有详细说明GLP-1药物的种类，并分析了在2005年3月至2018年11月期间开处GLP-1RA、胰岛素或二甲双胍的患者的数据。
Researchers found that patients using GLP-1 treatments had a significant reduction in the risk of ten cancers.
研究人员发现使用GLP-1治疗的患者患10种癌症的风险显著降低。
The authors noted this as "preliminary evidence of the potential benefit" of GLP-1 drugs in cancer prevention for high-risk populations and supported further preclinical and clinical studies to prevent certain obesity-associated cancers.
作者指出这是GLP-1药物在预防高风险人群特定肥胖相关癌症上“潜在益处的初步证据”，并支持进一步的临床前和临床研究。
Novo Nordisk's kidney outcomes trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression and cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo.
诺和诺德的肾脏结局试验通过展示8mg盐酸塞格列汀治疗者的肾脏疾病进展和心血管病和肾脏死亡的统计显著和优越的降低达到了主要终点。
In March, the FDA approved Wegovy to reduce the risk of stroke and heart attack in overweight or obese adults without diabetes.
三月份，FDA批准Wegovy用于减少超重或肥胖成人中中风和心脏病的风险。
Eli Lilly's detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide for obstructive sleep apnea achieved all primary and key secondary endpoints for both the efficacy and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index.
礼来关于治疗阻塞性睡眠呼吸暂停的替西妥肽的SURMOUNt-OSA第三期试验的详细结果达到了所有效力和治疗方案的主要和关键次要终点，并在呼吸暂停低通气指数上表现出高达62.8%的平均降低。
- ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential.
- ETF大规模押注减肥药概念，但行业观察人士怀疑其长期潜力。
Photo by Tobias Arhelger via Shutterstock
图片由shutterstock提供